Loading...
Cagrilintide
Add to Wishlist
Long-Acting Amylin Analog for Appetite Control
In Stock
Select Size
$90.00$108.00
You Save
$18.00In Stock — Ships Same Day
Includes
5mg research compound
Third-party lab tested
Free shipping on orders over $150
30-day money-back guarantee
Overview
Cagrilintide is a long-acting acylated amylin analog engineered with a C18 fatty diacid modification that enables albumin binding and extends its pharmacokinetic half-life to support once-weekly dosing protocols. Structurally derived from the 37-amino acid hormone amylin (islet amyloid polypeptide), which is co-secreted with insulin by pancreatic beta cells after meals, cagrilintide activates amylin receptors (AMY1 and AMY3) in the area postrema and hypothalamic nuclei to promote satiety, slow gastric emptying, and suppress postprandial glucagon secretion. Phase 2 clinical research published in The Lancet demonstrated dose-dependent body weight reductions of up to 10.8% over 26 weeks as a monotherapy, with even greater reductions observed when investigated in combination with semaglutide (the CagriSema combination). What distinguishes cagrilintide from GLP-1-based compounds is its activation of a complementary and non-overlapping satiety pathway — the amylin system — which may explain the additive efficacy observed in dual-pathway research. Ongoing Phase 3 trials are investigating cagrilintide both as a standalone agent and in fixed-ratio combination with semaglutide. This is a research-grade compound for laboratory investigation, not an FDA-approved product.
Handling & Storage
Published research protocols reference weekly subcutaneous administration. Store refrigerated at 2-8°C.
Published Research Protocols
Published research protocols reference gradual upward titration every 4 weeks. Consult applicable literature for specific research applications.
Research Applications
Amylin Pathway Activation
Selectively activates AMY1 and AMY3 amylin receptors in the area postrema and hypothalamus, engaging a satiety pathway that is mechanistically distinct from GLP-1 receptor signaling. This non-overlapping mechanism is the basis for investigating additive effects when combined with incretin-based compounds.
Initial effects within first month
Research Studies
Delayed Gastric Emptying
Slows gastric emptying through vagal afferent signaling and brainstem activation, prolonging nutrient contact with the intestinal wall and extending postprandial satiety. Published Phase 2 data showed dose-dependent reductions in food intake correlating with delayed gastric transit times.
Initial effects within first month
Research Studies
Weight Management
Phase 2 clinical research demonstrated up to 10.8% body weight reduction over 26 weeks as monotherapy, with significantly greater reductions observed in combination protocols with GLP-1 receptor agonists. Cagrilintide's caloric reduction appears driven by central nervous system satiety signaling rather than nausea-mediated appetite loss.
Initial effects within first month
Research Studies
Frequently Asked Questions
What makes Cagrilintide different from GLP-1 receptor agonists?
Cagrilintide activates the amylin receptor system (AMY1/AMY3) rather than the GLP-1 receptor. Amylin is a separate satiety hormone co-secreted with insulin from pancreatic beta cells. Because these are non-overlapping pathways, cagrilintide is being investigated in combination with GLP-1 agonists like semaglutide for potentially additive effects on appetite suppression and body weight.
How is Cagrilintide reconstituted for research?
Reconstitute the lyophilized cagrilintide with bacteriostatic water, injecting slowly along the vial wall. The acylated peptide structure dissolves readily. Do not shake. Once reconstituted, store at 2-8°C. The C18 fatty diacid modification provides enhanced stability compared to native amylin.
What is CagriSema and how does it relate to this product?
CagriSema is an investigational fixed-ratio combination of cagrilintide and semaglutide currently in Phase 3 clinical trials. This PEPCELL product contains cagrilintide as a standalone research compound. Researchers studying dual-pathway approaches may pair it with separate GLP-1 compounds in their protocols.
What purity and testing standards does PEPCELL Cagrilintide meet?
Every cagrilintide batch is third-party tested at Janoshik Analytical Laboratory via HPLC purity analysis and mass spectrometry identity confirmation. Current batches test at 99.3% purity with full Certificates of Analysis provided for each lot number.
Is Cagrilintide intended for human use?
Cagrilintide is sold exclusively for in-vitro research and laboratory investigation. It is not an FDA-approved drug product and is not intended for human consumption or self-administration. Consult published clinical literature and applicable regulations before designing any research protocol.
Important Notice
Not for human consumption. This product is sold exclusively for in-vitro research and laboratory use. It is not a drug, supplement, food item, or cosmetic and has not been evaluated by the FDA.
The research data and clinical references cited on this page are provided for educational reference only and do not constitute medical advice. This product must be handled by qualified research professionals in accordance with all applicable institutional and regulatory guidelines.
Use is restricted to qualified researchers or laboratories operating within appropriate legal and ethical research guidelines. By purchasing, you confirm you are acquiring this product solely for lawful research purposes.
